BACKGROUND: Neurocognitive impairment remains prevalent in HIV-infected (HIV+) individuals despite highly active antiretroviral therapy (HAART). We assessed the impact of HIV, HAART, and aging using structural neuroimaging. METHODS: Seventy-eight participants [HIV- (n = 26), HIV+ on stable HAART (HIV+/HAART+; n = 26), HIV+ naive to HAART (HIV+/HAART-; n = 26)] completed neuroimaging and neuropsychological testing. A subset of HIV+ subjects (n = 12) performed longitudinal assessments before and after initiating HAART. Neuropsychological tests evaluated memory, psychomotor speed, and executive function, and a composite neuropsychological score was calculated based on normalized performances (neuropsychological summary Z score, NPZ-4). Volumetrics were evaluated for the amygdala, caudate, thalamus, hippocampus, putamen, corpus callosum, and cerebral gray and white matter. A 3-group 1-way analysis of variance assessed differences in neuroimaging and neuropsychological indices. Correlations were examined between NPZ-4 and volumetrics. Exploratory testing using a broken-stick regression model evaluated self-reported duration of HIV infection on brain structure. RESULTS: HIV+ individuals had significant reductions in brain volumetrics within select subcortical regions (amygdala, caudate, and corpus callosum) compared with HIV- participants. However, HAART did not affect brain structure as regional volumes were similar for HIV+/HAART- and HIV+/HAART+. No association existed between NPZ-4 and volumetrics. HIV and aging were independently associated with volumetric reductions. Exploratory analyses suggest caudate atrophy due to HIV slowly occurs after self-reported seroconversion. CONCLUSIONS: HIV associated volumetric reductions within the amygdala, caudate, and corpus callosum occurs despite HAART. A gradual decline in caudate volume occurs after self-reported seroconversion. HIV and aging independently increase brain vulnerability. Additional longitudinal structural magnetic resonance imaging studies, especially within older HIV+ participants, are required.
BACKGROUND:Neurocognitive impairment remains prevalent in HIV-infected (HIV+) individuals despite highly active antiretroviral therapy (HAART). We assessed the impact of HIV, HAART, and aging using structural neuroimaging. METHODS: Seventy-eight participants [HIV- (n = 26), HIV+ on stable HAART (HIV+/HAART+; n = 26), HIV+ naive to HAART (HIV+/HAART-; n = 26)] completed neuroimaging and neuropsychological testing. A subset of HIV+ subjects (n = 12) performed longitudinal assessments before and after initiating HAART. Neuropsychological tests evaluated memory, psychomotor speed, and executive function, and a composite neuropsychological score was calculated based on normalized performances (neuropsychological summary Z score, NPZ-4). Volumetrics were evaluated for the amygdala, caudate, thalamus, hippocampus, putamen, corpus callosum, and cerebral gray and white matter. A 3-group 1-way analysis of variance assessed differences in neuroimaging and neuropsychological indices. Correlations were examined between NPZ-4 and volumetrics. Exploratory testing using a broken-stick regression model evaluated self-reported duration of HIV infection on brain structure. RESULTS: HIV+ individuals had significant reductions in brain volumetrics within select subcortical regions (amygdala, caudate, and corpus callosum) compared with HIV- participants. However, HAART did not affect brain structure as regional volumes were similar for HIV+/HAART- and HIV+/HAART+. No association existed between NPZ-4 and volumetrics. HIV and aging were independently associated with volumetric reductions. Exploratory analyses suggest caudate atrophy due to HIV slowly occurs after self-reported seroconversion. CONCLUSIONS: HIV associated volumetric reductions within the amygdala, caudate, and corpus callosum occurs despite HAART. A gradual decline in caudate volume occurs after self-reported seroconversion. HIV and aging independently increase brain vulnerability. Additional longitudinal structural magnetic resonance imaging studies, especially within older HIV+ participants, are required.
Authors: V A Cardenas; D J Meyerhoff; C Studholme; J Kornak; J Rothlind; H Lampiris; J Neuhaus; R M Grant; L L Chao; D Truran; M W Weiner Journal: J Neurovirol Date: 2009-07 Impact factor: 2.643
Authors: Jarek Harezlak; Steven Buchthal; Michael Taylor; Giovanni Schifitto; Jianhui Zhong; Eric Daar; Jeffrey Alger; Elyse Singer; Thomas Campbell; Constantin Yiannoutsos; Ronald Cohen; Bradford Navia Journal: AIDS Date: 2011-03-13 Impact factor: 4.177
Authors: Ronald A Cohen; Jaroslaw Harezlak; Assawin Gongvatana; Steven Buchthal; Giovanni Schifitto; Uraina Clark; Robert Paul; Michael Taylor; Paul Thompson; David Tate; Jeffery Alger; Mark Brown; Jianhui Zhong; Thomas Campbell; Elyse Singer; Eric Daar; Deborah McMahon; Yuen Tso; Constantin T Yiannoutsos; Bradford Navia Journal: J Neurovirol Date: 2010-10-20 Impact factor: 2.643
Authors: N Ciccarelli; M Fabbiani; S Di Giambenedetto; I Fanti; E Baldonero; L Bracciale; E Tamburrini; R Cauda; A De Luca; M C Silveri Journal: Neurology Date: 2011-04-19 Impact factor: 9.910
Authors: Robert K Heaton; Donald R Franklin; Ronald J Ellis; J Allen McCutchan; Scott L Letendre; Shannon Leblanc; Stephanie H Corkran; Nichole A Duarte; David B Clifford; Steven P Woods; Ann C Collier; Christina M Marra; Susan Morgello; Monica Rivera Mindt; Michael J Taylor; Thomas D Marcotte; J Hampton Atkinson; Tanya Wolfson; Benjamin B Gelman; Justin C McArthur; David M Simpson; Ian Abramson; Anthony Gamst; Christine Fennema-Notestine; Terry L Jernigan; Joseph Wong; Igor Grant Journal: J Neurovirol Date: 2010-12-21 Impact factor: 2.643
Authors: Robert H Paul; John A Joska; Carol Woods; Soraya Seedat; Susan Engelbrecht; Jacqueline Hoare; Jodi Heaps; Victor Valcour; Beau Ances; Laurie M Baker; Lauren E Salminen; Dan J Stein Journal: J Neurovirol Date: 2014-11-01 Impact factor: 2.643
Authors: C Paula Lewis-de Los Angeles; Paige L Williams; Yanling Huo; Shirlene D Wang; Kristina A Uban; Megan M Herting; Kathleen Malee; Ram Yogev; John G Csernansky; Sharon Nichols; Russell B Van Dyke; Elizabeth R Sowell; Lei Wang Journal: Brain Behav Immun Date: 2017-01-10 Impact factor: 7.217
Authors: Savvas Andronikou; Christelle Ackermann; Barbara Laughton; Mark Cotton; Nicollette Tomazos; Bruce Spottiswoode; Katya Mauff; John M Pettifor Journal: Childs Nerv Syst Date: 2014-05-23 Impact factor: 1.475
Authors: Laurie M Baker; Robert H Paul; Jodi M Heaps-Woodruff; Jee Yoon Chang; Mario Ortega; Zachary Margolin; Christina Usher; Brian Basco; Sarah Cooley; Beau M Ances Journal: J Neuroimmune Pharmacol Date: 2015-04-22 Impact factor: 4.147
Authors: Rosemary Fama; Edith V Sullivan; Stephanie A Sassoon; Adolf Pfefferbaum; Natalie M Zahr Journal: Alcohol Clin Exp Res Date: 2016-10-19 Impact factor: 3.455